1. Abi-Jaoudeh N, Dayyani F, Chen PJ, Fernando D, Fidelman N, Javan H, Liang PC, Hwang JI, Imagawa DK. Phase I trial on arterial embolization with hypoxia activated Tirapazamine for unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2021 May 17;8:421-434.
  2. Bai Y, Zhu B, Rovira-Clave X, Chen H, Markovic M, Chan CN, Su TH, McIlwain DR, Estes JD, Keren L, Nolan GP, Jiang S. Adjacent cell marker lateral spillover compensation and reinforcement for multiplexed images. Front Immunol. 2021 Jul 5;12:652-631.
  3. Boo YA, Chang MH, Jeng YM, Peng SF, Hsu WM, Lin WH, Chen HL, Ni YH, Hsu HY, Wu JF. Diagnostic ferformance of transient elastography in biliary atresia among infants with cholestasis. Hepatol Commun. 2021 Feb; 5(5):882-890.
  4. Chang KV, Wu WT, Huang KC, Han DS. Effectiveness of early versus delayed exercise and nutritional intervention on segmental body composition of sarcopenic elders-A randomized controlled trial. CLINICAL NUTRITION.2021 Mar 40:(3):1052-1059. 
  5. Chao T, Shih HT, Hsu SC, Chen PJ, Fan YS, Jeng YM, Shen ZQ, Tsai TF, Chang ZF. Autophagy restricts mitochondrial DNA damage-induced release of ENDOG (endonuclease G) to regulate genome stability. Autophagy. 2021 Nov;17(11):3444-3460. 
  6. Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021 Jun;41(6):1265-1277. 
  7. Chen HH, Kao JH, Chen JS, Ni YH. What we have learned from COVID-19 pandemic? J Formos Med Assoc. 2021;120 (Suppl 1):S1-S5.
  8. Chen KY, Tseng JH, Ho MC, Lee RC, Liang PC, Liao LY, Huang KW, Hu JT, Liang JD, Wang SY, Kee KM, Lin CL, Lin SM, Wang CK, Lu SN, Wang JH, Lee WC, Chen CH, Liu CJ, Huang YH, Wang CC, Wang TE, Chuang PH, Dai CY, Hsu C, Shao YY, Chen SC, Hsieh CH. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2021 Apr;120(4):1051-1060
  9. Chen YH, Chen HL, Ho CM, Chen HY, Ho SL, Hu RH, Lee PH, Chang MH. Preclinical application of reduced manipulated processing strategy to collect transplantable hepatocytes: a pilot and feasibility study. J Pers Med. 2021 Apr 21;11(5):326.
  10. Cheng HR, Yang HC, Lin SR, Yang TY, Lin YY, Su TH, Tseng TC, Liu CJ, Kao JH. Correction to: Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. Hepatol Int. 2021 Dec;15(6):1466-1467.
  11. Cheng HY, Huang KW, Liang JT, Lin BR, Huang J, Hung JS, Chen CL. Multielectrode radiofrequency ablation for resectable metachronous liver metastasis from colorectal cancer. J Clin Med. 2021 Aug 20;10(16):3712.
  12. Cheng YM, Kao JH, Wang CC. The metabolic profiles and body composition of lean metabolic associated fatty liver disease. Hepatol Int. 2021 Apr;15(2):405-412.
  13. Cheng YW, Chao TL, Li CL, Wang SH, Kao HC, Tsai YM, Wang HY, Hsieh CL, Lin YY, Chen PJ, Chang SY, Yeh SH. D614G Substitution of SARS-CoV-2 Spike Protein increases syncytium formation and virus titer via enhanced furin-mediated spike cleavage. mBio. 2021 Aug 31;12(4):e0058721.
  14. Chiang CM, Hsu WM, Chang MH, Hsu HY, Ni YH, Chen HL, Wu JF. Risk factors and management for anastomotic stricture after surgical reconstruction of esophagealatresia. J Formos Med Assoc 2021 Jan; 120(1 Pt 2):404-410.
  15. Chien MM, Chang MH, Chang KC, Chiu YC, Chen HL, Hsu HY, Wu JF. The characteristics of pediatric ulcerative colitis with primary sclerosing cholangitis: A single-center study in Taiwan. Pediatr Neonatol. 2021 Sep; 62(5):483-490.
  16. Chuang WL, Hu TH, Buggisch P, Moreno C, Su WW, Biancone L, Camargo M, Hyland R, Lu S, Kirby BJ, Dvory-Sobol H, Osinusi A, Gaggar A, Peng CY, Liu CH, Sise ME, Mangia A. Ledipasvir/Sofosbuvir for 8, 12, or 24 weeks in hepatitis C patients undergoing dialysis for end-stage renal disease. Am J Gastroenterol. 2021 Sep 1;116(9):1924-1928.
  17. Han DS, Wu WT, Hsu PC, Chang HC, Huang KC, Chang KV. Sarcopenia is associated with increased risks of rotator cuff tendon diseases among community-dwelling elders: a cross-sectional quantitative ultrasound study. Front Med (Lausanne). 2021 May 5;8:630009. 
  18. Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren MH, Kossenkov A, Sanseviero E, Raulf N, Vasara J, Andrikakou P, Meyer T, Huang KW, Plummer R, Chee CE, Spalding D, Pai M, Khan S, Pinato DJ, Sharma R, Basu B, Palmer D, Ma YT, Evans J, Habib R, Martirosyan A, Elasri N, Reynaud A, Rossi JJ, Cobbold M, Habib NA, Gabrilovich DI. Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin Cancer Res. 2021 Nov 1;27(21):5961-5978.
  19. Ho CM, Chen CL, Chang CH, Lee MR, Wang JY, Hu RH, Lee PH. Circulatory inflammatory mediators in the prediction of anti-tuberculous drug-induced liver injury using RUCAM for causality assessment. Biomedicines 2021 Jul;9(8):891
  20. Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival after treatable hepatocellular carcinoma recurrence in liver recipients: A nationwide cohort analysis. Front Oncol. 2021 Jan; 10:616094.
  21. Ho CM, Wang JY, Yeh CC, Hu RH, Lee PH. Experience of applying threshold concepts in medical education. J Formos Med Assoc. 2021 Apr;120(4):1121-1126.
  22. Ho CM, Yeh CC, Wang JY, Hu RH, Lee PH. Preclass online video learning and class style expectation: Patterns, association, and precision medical education. Annals of Medicine 2021 Dec;53(1):1390-1401
  23. Hong CM, Lin YY, Liu CJ, Lai YY, Yeh SH, Yang HC, Kao JH, Hsu SJ, Huang YH, Yang SS, Kuo HT, Cheng PN, Yu ML, Chen PJ. Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan. Viruses 2021 Nov 17;13(11):2294.
  24. Hsiao CY, Ho MC, Ho CM, Wu YM, Lee PH, Hu RH. Long-term tacrolimus blood trough level and patient survival in adult liver transplantation. J Pers Med. 2021 Feb; 11(2):90.
  25. Hsiao CY, Teng X, Su TH, Lee PH, Kao JH, Huang KW. Improved second harmonic generation and two-photon excitation fluorescence microscopy-based quantitative assessments of liver fibrosis through auto-correction and optimal sampling. Quant Imaging Med Surg. 2021 Jan;11(1):351-361.
  26. Hsiao CY, Yang PC, Huang KW. Linear radiofrequency ablation using dual switching-control mode achieves rapid and bloodless liver resection, an experimental research. Int J Hyperthermia. 2021;38(1):357-362.
  27. Hsieh MH, Bair MJ, Tsai PC, Tseng KC, Lo CC, Chen CY, Kuo HT, Hung CH, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, Yu ML, Chuang WL; T-COACH investigators. Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. J Gastroenterol Hepatol. 2021 Aug;36(8):2247-2254.
  28. Hsu CY, Wang JT, Huang KC, Fan AC, Yeh YP, Chen SL. Household transmission but without the community-acquired outbreak of COVID-19 in Taiwan. J Formos Med Assoc. 2021 Jun;120 Suppl 1:S38-S45. 
  29. Hsu HY, Chen HL, Wu JF, Ni YH, Chang KC, Chiang CL, Lee CN, Zhao LL, Lai MW, Mu SC, Wen WH, Lin LH, Chang MH; Taiwan Study Group for the Prevention of Mother-to-InfantTransmission of HBV (PreMIT study). Occult hepatitis B virus infection in immunized infants born to untreated and tenofovir-treated highly viremic mothers. Clin Gastroenterol Hepatol 2021 Jul; 19(7):1494-1496.
  30. Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, Yu ML, Peng CY. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol. 2021 Oct;36(10):2884-2892.
  31. Huang CF, Kuo HT, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH, Lin HC, Chuang WL, Chen CY, Tseng KC, Yu ML. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Sci Rep 2021 Dec 6;11(1):23473.
  32. Huang KW, Tan CP, Reebye V, Chee CE, Zacharoulis D, Habib R, Blakey DC, Rossi JJ, Habib N, Sodergren MH. MTL-CEBPA combined with immunotherapy or RFA enhances immunological anti-tumor response in preclinical models. Int J Mol Sci. 2021 Aug 25;22(17):9168.
  33. Huang SC, Liao SH, Su TH, Jeng YM, Kao JH. Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma. Hepatol Int. 2021 Apr;15(2):472-481
  34. Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, Liu CJ. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease. Gut Liver. 2021 May 15;15(3):451-458.
  35. Jeng WJ, Chen CH, Yang HI, Tseng TC, Liu YC, Chen YC, Peng CY, Hu TH, Hung CH, Wang, JH, Lu SN, Kao JH, Chien RN, Liaw YF. Comparison of long-term clinical outcomes between patients with spontaneous and off-NUC HBsAg seroclearance. Hepatology 2021 74: 474A-474A
  36. Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021 Aug;15(4):833-851.
  37. "Kuo KL, Chen HM, Hsiao SH, Chu D, Huang SJ, Huang KC, Huang CY. The relationship between anthropometric factors and hyperuricemia in adolescent athletes. Obes Res Clin Pract
  38. . Jul-Aug 2021;15(4):375-380"
  39. Lee WC, Chen TK, Han HF, Lin YC, Hwang YM, Kao JH, Chen PJ, Liu CJ. Investigating the prevalence and clinical effects of hepatitis delta viral infection in Taiwan. J Microbiol Immunol Infect. 2021 Oct;54(5):901-908.
  40. Li YT, Wu HL, Liu CJ. Molecular mechanisms and animal models of HBV-related hepatocellular carcinoma: with emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci. 2021 Aug 29;22(17):9380.
  41. Liao SH, Chen CL, Hsu CY, Chien KL, Kao JH, Chen PJ, Chen TH, Chen CH. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J Hepatol. 2021 Jul;75(1):132-141.
  42. Lin CC, Chen TH, Wu YC, Fang CY, Wang JY, Chen CP, Huang KW, Jiang JK. Taiwan society of colon and rectal surgeons (TSCRS) consensus for cytoreduction selection in metastatic colorectal cancer. Ann Surg Oncol. 2021 Mar;28(3):1762-1776.
  43. Lin CL, Kao JH. Response to letter to the editor "Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy". J Formos Med Assoc. 2021 Feb; 120(2):915-917.
  44. Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, Yang SS, Su WW, Wu JC, Lee TH, Peng CY, Tseng KC, Qin A, Huang YW, Chen PJ. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open. 2021 Jul 10;5(8):929-940.
  45. Lin HY, Ho CM, Hsieh PY, Lin MH, Wu YM, Ho MC, Lee PH, Hu RH. Circuitous path to live donor liver transplantation from the coordinator’s perspective. J Pers Med. 2021 Nov 10;11(11):1173.
  46. Lin PH, Liang CY, Yao BY, Chen HW, Pan CF, Wu LL, Lin YH, Hsu YS, Liu YH, Chen PJ, Hu CJ, Yang HC. Robust induction of T(RM)s by combinatorial nanoshells confers cross-strain sterilizing immunity against lethal influenza viruses. Mol Ther Methods Clin Dev. 2021 Mar 23;21:299-314.
  47. Lin SR, Yang TY, Peng CY, Lin YY, Dai CY, Wang HY, Su TH, Tseng TC, Liu IJ, Cheng HR, Shen YC, Wu FY, Liu CJ, Chen DS, Chen PJ, Yang HC, Kao JH. Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters.   JHEP Rep. 2021 Feb; 3(3):100254.
  48. Lin YC, Chang PF, Liu K, Chang MH, Ni YH. Predictors for incidence and remission of nonalcoholic fatty liver disease in obese children and adolescents. J Formos Med Assoc. 2022 Jan;121(1 Pt 1):36-42.
  49. Lin YJ, Ho CM. Is the rationale of anatomical liver resection for hepatocellular carcinoma universally adoptable? A hypothesis-driven review. Medicina (Kaunas). 2021 Feb; 57(2):131.
  50. Liu CH, Chen CY, Su WW, Tseng KC, Lo CC, Liu CJ, Chen JJ, Peng CY, Shih YL, Yang SS, Huang CS, Huang KJ, Chang CY, Tsai MC, Kao WY, Fang YJ, Chen PY, Su PY, Tseng CW, Huang JJ, Lee PL, Lai HC, Hsieh TY, Chang CH, Huang YJ, Lee FJ, Chang CC, Kao JH. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. Gut. 2022 Jan;71(1):176-184. 
  51. Liu CH, Chen PY, Chen JJ, Lo CC, Su WW, Tseng KC, Liu CJ, Huang CS, Huang KJ, Yang SS, Peng CY, Tsai MC, Kao WY, Chang CY, Shih YL, Fang YJ, Chen CY, Lee PL, Huang JJ, Su PY, Tseng CW, Hung CC, Chang CH, Huang YJ, Lai HC, Chang CC, Lee FJ, Hsieh TY, Kao JH. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. Hepatol Int. 2021 Apr;15(2):338-349.
  52. Liu CH, Kao JH. Last Mile to Microelimination of hepatitis C virus infection among people living with human immunodeficiency virus. Clin Infect Dis. 2021 Oct 5;73(7):e2172-e2174.
  53. Liu CH, Kao JH. Reply to: "Sofosbuvir and the risk of kidney dysfunction". J Hepatol. 2021 Jan;74(1):257-258.
  54. Liu CH, Sun HY, Hsieh SM, Liu WC, Sheng WH, Liu CJ, Su TH, Tseng TC, Chen PJ, Hung CC, Kao JH. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy. J Viral Hepat. 2021 Jun;28(6):887-896.
  55. Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie Q, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, Yu ML, Kao JH, Yang HI, Nguyen MH. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatol Int. 2021 Feb;15(1):71-81.
  56. Lu CW, Lee YC, Kuo CS, Chiang CH, Chang HH, Huang KC. Association of serum levels of Zinc, Copper, and iron with risk of metabolic syndrome. Nutrients 2021 Feb 13: 548 (2):3390.
  57. Mo YH, Chen HL, Hsu WM, Chang CH, Peng SS. A noninvasive index to predict liver cirrhosis in biliary atresia. Pediatr Radiol. 2021 Feb; 51(2):257-264.
  58. Soong TK, Ho CM. Artificial intelligence in medical OSCEs: Reflections and future developments. Adv Med Educ Pract. 2021 Feb; 12:167-173.
  59. Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc. 2022 Jan;121(1 Pt 1):202-209.
  60. Su TH, Hu TH, Chuang WL, Su WW, Lin CC, Peng CY, Wang CC, Hsu YC, Huang YW, Tseng, KC, Lin CL, Yang SS, Suk FM, Hsu SJ, Chen TM, Bair MJ, Lin CK, Hsieh TY, Wang HY, Tseng TC, Kao JH. Eight-year Entecavir therapy continuously reduces liver adverse events in chronic hepatitis B patients with cirrhosis. Hepatology 2021 74: 481A-482A
  61. Su TH, Kao JH. Withdrawal of nucleos(t)ide analogues in hepatitis B e antigen-negative patients: an asian perspective. Clin Liver Dis (Hoboken). 2021 Jan; 16(6):244-248.
  62. Su TH, Liao CH, Liu CJ, Yang HC, Liou JM, Hong CM, Tseng TC, Liu CH, Kao JH. High FIB-4 index predicts liver decompensation after discontinuation of antiviral therapy in patients of chronic hepatitis B. hepatology 2021 74: 484A-485A.
  63. Su TH, Wu CH, Kao JH. Artificial intelligence in precision medicine in hepatology. J Gastroenterol Hepatol. 2021 Mar;36(3):569-580.
  64. Sung CC, Horng JH, Siao SH, Chyuan IT, Tsai HF, Chen PJ, Hsu PN. Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus. Cell Mol Immunol. 2021 Jul;18(7):1772-1782.
  65. Teng W, Chang TT, Yang HI, Peng CY, Su CW, Su TH, Hu TH, Yu ML, Yang HC, Wu JC. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatol Int. 2021 Dec;15(6):1421-1430.
  66. Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Ke CK, Yu ML. Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis C patients: a nationwide real-world Taiwanese cohort (T-COACH). Open Forum Infect Dis. 2020 Aug 31;7(10):ofaa397. 
  67. Tseng H, Ho CM, Tien YW. Reappraisal of surgical decision-making in patients with splenic sclerosing angiomatoid nodular transformation: Case series and literature review. World J Gastrointest Surg. 2021 Aug 27;13(8):848-858.
  68. Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh HN, Wong C, Wong C, Zhang J, Li J, Kao JH. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment Hepatol Int. 2021 Feb;15(1):105-113.
  69. Tseng TC, Kao JH. Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection-authors' reply Aliment Pharmacol Ther. 2021 Jan;53(1):203-204.
  70. Tseng TC, Liu CJ, Yang WT, Hsu CY, Hong CM, Su TH, Tsai CH, Chen CL, Yang HC, Liu CH, Chen HH, Chen PJ, Kao JH. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther. 2021 Apr; 53(8):908-918.
  71. van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Shneider BL, Sokal E, Grammatikopoulos T, Kadaristiana A, Jacquemin E, Spraul A, Lipiński P, Czubkowski P, Rock N, Shagrani M, Broering D, Algoufi T, Mazhar N, Nicastro E, Kelly D, Nebbia G, Arnell H, Fischler B, Hulscher JBF, Serranti D, Arikan C, Debray D, Lacaille F, Goncalves C, Hierro L, Muñoz Bartolo G, Mozer-Glassberg Y, Azaz A, Brecelj J, Dezsőfi A, Luigi Calvo P, Krebs-Schmitt D, Hartleif S, van der Woerd WL, Wang JS, Li LT, Durmaz Ö, Kerkar N, Hørby Jørgensen M, Fischer R, Jimenez-Rivera C, Alam S, Cananzi M, Laverdure N, Ferreira CT, Ordonez F, Wang H, Sency V, Kim KM, Chen HL, Carvalho E, Fabre A, Quintero Bernabeu J, Alonso EM, Sokol RJ, Suchy FJ, Loomes KM, McKiernan PJ, Rosenthal P, Turmelle Y, Rao GS, Horslen S, Kamath BM, Rogalidou M, Karnsakul WW, Hansen B, Verkade HJ. Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency. Hepatology. 2021 Aug; 74(2):892-906.
  72. Wang CC, Tseng KC, Tzeng IS, Kao JH. The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma. J Formos Med Assoc. 2021 Mar; 120(3):965-973.
  73. Wang SH, Yeh SH, Chen PJ. Unique features of hepatitis B virus-related hepatocellular carcinoma in pathogenesis and clinical significance. Cancers (Basel). 2021 May 18;13(10):2454.
  74. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021 Mar 18;384(11):989. 
  75. Wu CH, Liang PC, Su TH, Lin MC, Chang YH, Shih TT, Kao JH. Iodized oil computed tomography versus ultrasound-guided radiofrequency ablation for early hepatocellular carcinoma. Hepatol Int 2021 Oct;15(5):1247-1257.
  76. Wu IU, Tsai JH, Ho CM. Fatal acute-on-chronic liver failure in amiodarone-related steatohepatitis: A case report. BMC Gastroenterol. 2021 Feb; 21(1):50.
  77. Wu JF, Boo YA, Ho MC, Chen HL, Hsu HY, Chang MH. Serum bile acid levels assist the prediction of biliary stricture and survival after liver transplantation in children. Eur J Pediatr. 2021 Aug;180(8):2539-2547.
  78. Wu JF, Chang KC, Ni YH, Hsu HY, Chang MH. Impacts of the percentage of basal core promoter mutation on the progression of liver fibrosis after HBeAg-seroconversion. J Infect Dis 2021 Apr; 223(8):1381-1389.
  79. Wu JW, Kao JH, Tseng TC. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma. Clin Mol Hepatol. 2021 Oct;27(4):524-534.
  80. Wu LL, Huang TS, Shyu YC, Wang CL, Wang HY, Chen PJ. Gut microbiota in the innate immunity against hepatitis B virus - implication in age-dependent HBV clearance. Curr Opin Virol. 2021 Aug;49:194-202.
  81. Wu SH, Chang MH, Chen YH, Wu HL, Chua HH, Chien CS, Ni YH, Chen HL, Chen HL. The ESCRT-III molecules regulate the apical targeting of bile salt export pump. J Biomed Sci. 2021 Mar; 28(1):19.
  82. Wu WK, Chen YH, Lee PC, Yang PJ, Chang CC, Liu KL, Hsu CC, Huang CC, Chuang HL, Sheen LY, Liu CJ, Wu MS. Mining gut microbiota from bariatric surgery for MAFLD. Front Endocrinol (Lausanne). 2021 Apr 9;12:612946
  83. Wu YL, Tseng TC, Tsai YN, Tseng CH, Chen CY, Lin JT, Nguyen MH, Kao JH, Hsu YC. Antiviral treatment with tenofovir disoprpxil fumarate decreases serum levels of hepatitis B core-related antigen and viral RNA in chronic hepatitis B patients. Hepatology. 2021 74: 428A-429A
  84. Yang HC. Isolation or de-isolation? Measuring the infectivity of severe acute respiratory syndrome coronavirus 2. Clin Infect Dis. 2021 Nov 2;73(9):e2960-e2961.
  85. Yang PC, Chen YJ, Li XY, Hsiao CY, Cheng BB, Gao Y, Zhou BZ, Chen SY, Hu SQ, Zeng Q, Huang KW. Irreversible electroporation treatment with intraoperative biliary stenting for unresectable perihilar cholangiocarcinoma: a pilot study. Front Oncol. 2021 Jun 30;11:710536.
  86. Yeh ML, Hung CH, Tseng KC, Lai HC, Chen CY, Kuo HT, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang CF, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Liu CJ, Yu ML. Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Hepatol Int. 2021 Oct;15(5):1109-1121.
  87. Yu LCH, Wei SC, Li YH, Lin PY, Chang XY, Weng JP, Shue YW, Lai LC, Wang JT, Jeng YM, Ni YH. Invasive pathobionts contribute to colon cancer initiation by counterbalancing epithelial antimicrobial responses. Cell Mol Gastroenterol Hepatol. 2022;13(1):57-79.
  88. Yu ML, Kao JH. Reply to "Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia". J Formos Med Assoc. 2021 Jun;120(6):1410-1411